Company: KROS
Filing Date: 2025-10-20
Form Type: SC TO-I
Source: 0001104659-25-100554
Chunk: 3

Company: Keros Therapeutics, Inc.
Filing Date: 2025-10-20
Form: SC TO-I
Chunk 3
---
 Section 2 (“Purpose of the Tender Offer; Certain Effects of the Tender Offer”) and Section 11 (“Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares.”) is incorporated herein by reference.

## ITEM 7.
SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

(a)

The information regarding the source of funds set forth in the Offer to Purchase under Section 9 (“Source and Amount of Funds”) is incorporated herein by reference.

(b)

None.

(c)

The information regarding expenses set forth in the Offer to Purchase under Section 16 (“Fees and Expenses”) is incorporated herein by reference.

(d)

None.

## ITEM 8.

#### INTEREST IN SECURITIES OF THE SUBJECT COMPANY.
(a) and (b)

The information set forth in the Offer to Purchase under Section 11 (“Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares”) is incorporated herein by reference.

## ITEM 9.
PERSONS/ASSETS, RETAINED, EMPLOYED, COMPENSATED OR USED.

(a)

The information set forth in the Offer to Purchase under the heading “Summary Term Sheet” and Section 16 (“Fees and Expenses”) is incorporated herein by reference.

## ITEM 10.

### FINANCIAL STATEMENTS.
(a) and (b)

Not applicable.

<div align='center'>2</div>

ITEM 11. ADDITIONAL INFORMATION. (a)(1) The information set forth in the Offer to Purchase under the heading “Summary Term Sheet” and Section 10 (“Certain Information Concerning the Company”) and Section 11 (“Interests of Directors and Executive Officers; Transactions and Arrangements Concerning the Shares”) is incorporated herein by reference. The Company will amend this Schedule TO to reflect material changes to information incorporated by reference in the Offer to Purchase to the extent required by Rule 13e-4(d)(2). (a)(2) The information set forth in the Offer to Purchase under Section 13 (“Legal Matters; Regulatory Approvals”) is incorporated herein by reference. (a)(3) The information set forth in the Offer to Purchase under Section 13 (“Legal Matters; Regulatory Approvals”) is incorporated herein by reference. (a)(4) The information set forth in the Offer to Purchase under Section 2 (“Purpose of the Tender Offer; Certain Effects of the Tender Offer; Other Plans”) and Section 12 (“Effects of the Tender Offer on the Market for Shares; Registration under the Exchange